A Study of Huperzine A Injection in Reducing Postoperative Delirium in Elderly Patients Undergoing Non-cardiac Surgery

Launched by SECOND AFFILIATED HOSPITAL OF WENZHOU MEDICAL UNIVERSITY · Feb 6, 2022

Keywords

ClinConnect Summary

This clinical trial is studying a medication called Huperzine A Injection to see if it can help reduce a condition known as postoperative delirium in older patients after they have non-cardiac surgery. Postoperative delirium can cause confusion and changes in mental state, which are especially concerning for elderly patients. The goal is to find out if this injection can help patients feel better and recover more smoothly after their surgery.

To participate in this trial, individuals must be at least 75 years old and scheduled for a non-cardiac surgery that requires general anesthesia. They will need to give their consent to join the study. However, certain patients won't be eligible, such as those with severe kidney or liver issues, recent infections, or previous history of delirium. Participants can expect to receive the Huperzine A Injection during their surgery and will be monitored to see how well it works in preventing delirium. It's important to note that the study is currently recruiting participants, so if you or someone you know fits the criteria and is interested, there may be an opportunity to join.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • ≥ 75 years old.
• • Comply with the indication of non-cardiac surgery under general anesthesia.
• • Anesthesia grade of American Society of Anesthesiologist (ASA) as III\~IV grade.
• • The estimated operation time ≥ 2 hours.
• • Voluntarily sign the informed consent form.
• Exclusion Criteria:
• • Patients with impaired renal function (Cr is 1.5 times higher than the upper limit of the normal value of the central laboratory) or abnormal liver function (Alanine aminotransferase(ALT) and Aspartate aminotransferase(AST) are 2 times higher than the upper limit of the normal value of the central laboratory).
• • Patients who are positive for infectious diseases.
• • Patients accompanied with central nervous system injury.
• • Patients with previous history of delirium and epilepsy, long-term use of psychoactive drugs or preoperative assessment of delirium.
• • Patients who involved diseases with drug taboos, bronchial asthma, mechanical intestinal obstruction and urinary tract obstruction, or serious systemic diseases, especially circulatory diseases: such as myocardial infarction, heart failure, angina pectoris, history of sinus bradycardia.
• • Patients who are known to be allergic to narcotic drugs or Huperzine A Injection, or must use drugs that are not compatible with Huperzine An Injection.
• • patients who participated in other clinical trials within 3 months before this study, for any reason, who could not tolerate the test or cooperate with the examination, or who has any aphasia, audio-visual dysfunction, etc.
• • the investigators think that the patients is not suitable to participate in this study.